Related references
Note: Only part of the references are listed.
Article
Immunology
A. Uruena et al.
Summary: The study showed that long-term memory immune response to single-dose hepatitis A virus vaccination persists after an average follow-up of 12 years, indicating the potential protective role even with waning antibodies.
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Article
Microbiology
Diego S. Ojeda et al.
Summary: We developed and applied a robust serologic test in Argentina for evaluating antibody responses to SARS-CoV-2. The test, COVIDAR IgG and IgM, have been widely distributed and used for assessing immune responses, convalescent plasma programs, and large seroprevalence studies. The study provided valuable insights into antibody kinetics in infected individuals and supported policy-making for managing the pandemic.
Letter
Medicine, General & Internal
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Joseph E. Ebinger et al.
Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Sebastian Havervall et al.
Summary: The study compared antibody levels in healthcare workers previously infected with SARS-CoV-2 who received a single dose of ChAdOx1 nCoV-19 vaccine and SARS-CoV-2 naive participants who received two doses of BNT162b2 vaccine, finding higher immune response in the former.
Article
Cell Biology
Ming-Liang Ma et al.
Summary: One of the best ways to control COVID-19 is through vaccination with inactivated virus vaccines, which have been widely used in China and other countries. By analyzing humoral responses triggered by these vaccines, potential biomarkers for assessing vaccine effectiveness can be identified, as well as biomarkers for differentiating COVID-19 patients from vaccinated individuals.
